Primary care prescribing patterns in Ireland after the publication of large hypertension trials

British Journal of Clinical Pharmacology

Volumn 64, Issue 3, 2007, Pages 381-385

  Kabir, Zubair ^a   Feely, John ^a   Bennett, Kathleen ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Antihypertensive; Prescribing; Trials

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; LOSARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ARTICLE; CLINICAL PRACTICE; DATA BASE; HUMAN; HYPERTENSION; IRELAND; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUBLICATION; REGRESSION ANALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; IRELAND; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PRIMARY HEALTH CARE;

EID: 34548021424     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02896.x     Document Type: Article

References (20)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005 365 : 217 23.
2. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 : 995 1003.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 288 : 2981 97.
4. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 363 : 2022 31.
5. Xie F, Petitti DB, Chen W. Prescribing patterns for anti-hypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Report of experience in a Health Maintenance Organization. Am J Hypertens 2005 18 : 464 9.
6. Austin PC, Mamdani MM, Tu K, Zwarenstein M. Changes in prescribing patterns following publication of the ALLHAT trial. JAMA 2004 291 : 44 5.
7. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002 27 : 299 309.
8. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000 342 : 145 53.
9. Fox KM, Henderson JR, Bertrand ME, Ferrari R, Remme WJ, Simoons ML. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998 suppl. J : J52 5.
10. Dunn DR. Dissemination of the published results of an important clinical trial: an analysis of the citing literature. Bull Med Libr Assoc 1981 69 : 301 6.
11. Reiffel JA, Cook JR. Physician attitudes toward the use of type IC antiarrhythmics after the Cardiac Arrhythmia Suppression Trial (CAST). Am J Cardiol 1990 66 : 1262 4.
12. Flottorp S, Oxman AD. Identifying barriers and tailoring interventions to improve the management of urinary tract infections and sore throat: a pragmatic study using qualitative methods. BMC Health Serv Res 2003 3 : 3.
13. Oxman AD, Flottorp S, Silagy C, Haines A. An overview of strategies to promote implementation of evidence-based health care. In Evidence-based practice in Primary Care, London : BMJ Books, 2001 pp. 101 19.
14. Fretheim A, Oxman AD, Håvelsrud K, Treweek S, Kristoffersen DT, Bjorndal A. Rational prescribing in primary care (RaPP): a cluster randomized trial of a tailored intervention. Plos Med 2006 3 : e134.
15. Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension 2000 36 : 600 3.
16. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG. Thom British Hypertension Society. Guidelines for management of hypertension: report of the fourth Working Party of the British Hypertension Society, BHSIV. J Hum Hypertens 2004 18 : 139 85.
17. Mottur-Pilson C, Snow V, Bartlett K. Physician explanations for failing to comply with 'best practices.' Eff Clin Pract 2001 4 : 207 13.
18. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999 282 : 1458 65.
19. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 366 : 895 906.
20. Mayor S. NICE removes beta blockers as first line treatment for hypertension. BMJ 2006 333 : 8.